News | Heart Failure | June 24, 2015

Scott & White Memorial Uses CardioMEMS HF System to Help Heart Failure Patients

Hospital is sixth in Texas to adopt new remote monitoring device for heart failure

CardioMEMS, Scott & White Memorial, Texas, heart failure, remote monitoring

June 24, 2015 ­- Scott & White Memorial – Temple for the first time implanted a new miniaturized, wireless monitoring sensor to help manage heart failure (HF). Scott & White Memorial is one of six hospitals in Texas and the first hospital in the Baylor Scott & White Health system to offer the device.

"We are always looking for new and innovative ways to treat our patient's disease process and improve outcomes for heart failure patients," said Robert Scott III, M.D., director for advanced heart failure at Scott & White Memorial. "This device will give us the ability to anticipate problems with our patients before they occur, decreasing their chance of being re-admitted to the hospital, and improving their quality of life."

Memorial implemented the CardioMEMS HF System, a U.S. Food and Drug Administration (FDA)-approved heart failure monitoring device proven to significantly reduce hospital admissions.

The device is a sensor that is implanted in the pulmonary artery (PA) during a minimally invasive procedure. Once implanted, the device can measure and transmit PA pressure from the patient back to their healthcare team. Elevation in PA pressure appears even before changes in weight and blood pressure in the patient, which are traditionally used as indirect measures of worsening heart failure. The new system allows patients to transmit daily sensor readings from their homes to their healthcare providers allowing for personalized and proactive management to reduce the likelihood of hospitalization and onset of debilitating symptoms.

"Heart failure can rob patients' quality of life and frequently results in repeated hospitalizations," said John Erwin III, M.D., cardiologist at Scott & White Memorial. "We think that we can provide significantly improved quality of life by partnering with the patient in acting preventatively as opposed to responding when an adverse event occurs."

For more information: www.sw.org

Related Content

Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Overlay Init